158 related articles for article (PubMed ID: 17680023)
1. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma.
Tiwari D; Gao F; Hidalgo J; Adkins DR; Vij R; DiPersio JF; Khoury HJ
Bone Marrow Transplant; 2007 Oct; 40(7):671-5. PubMed ID: 17680023
[TBL] [Abstract][Full Text] [Related]
2. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma.
Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Moreb JS
Bone Marrow Transplant; 2003 Jun; 31(11):1009-13. PubMed ID: 12774052
[TBL] [Abstract][Full Text] [Related]
3. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
4. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
[TBL] [Abstract][Full Text] [Related]
5. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN
Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015
[TBL] [Abstract][Full Text] [Related]
6. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
7. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target.
Katipamula R; Porrata LF; Gastineau DA; Markovic SN; Moore SB; Greiner C; Burgstaler EA; Padley DJ; Winters JL
Bone Marrow Transplant; 2006 May; 37(9):811-7. PubMed ID: 16532018
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
Porrata LF; Ingle JN; Litzow MR; Geyer S; Markovic SN
Bone Marrow Transplant; 2001 Nov; 28(9):865-71. PubMed ID: 11781647
[TBL] [Abstract][Full Text] [Related]
9. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation.
Cetkovský P; Koza V; Jindra P; Skopek P; Svojgrová M
Bone Marrow Transplant; 1997 Oct; 20(8):639-41. PubMed ID: 9383226
[TBL] [Abstract][Full Text] [Related]
10. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
11. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
Hoerr AL; Gao F; Hidalgo J; Tiwari D; Blum KA; Mathews V; Adkins DR; Blum W; Devine S; Vij R; Goodnough LT; Dipersio JF; Khoury HJ
J Clin Oncol; 2004 Nov; 22(22):4561-6. PubMed ID: 15542807
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma.
Kim H; Sohn HJ; Kim SE; Kang HJ; Park S; Kim S; Kim WK; Lee JS; Suh C
Bone Marrow Transplant; 2004 Jul; 34(1):43-9. PubMed ID: 15107814
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
15. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
[TBL] [Abstract][Full Text] [Related]
16. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
[TBL] [Abstract][Full Text] [Related]
17. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
Atta EH; de Azevedo AM; Maiolino A; Coelho CJ; Sarcinelli SM; de Alvarenga Máximo C; Marra VL
Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
20. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]